These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36877951)

  • 41. [Systemic chemotherapy of urothelial cancer].
    Wolff JM; Jakse G
    Urologe A; 1992 May; 31(3):W19-24. PubMed ID: 1615589
    [No Abstract]   [Full Text] [Related]  

  • 42. Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma.
    Tural D; Selçukbiricik F; Ölmez ÖF; Sümbül AT; Erman M; Coşkun HŞ; Artaç M; Kılıçkap S
    Int J Clin Oncol; 2022 Mar; 27(3):585-591. PubMed ID: 34762201
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The application of hematopoietic growth factors in advanced transitional cell carcinoma of the urinary tract.
    de Mulder PH; Sternberg CN; van Oosterom AT; Fossa SD
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):65-9. PubMed ID: 7512278
    [No Abstract]   [Full Text] [Related]  

  • 44. Accelerated chemotherapy in the treatment of urothelial cancer.
    Huddart RA; Lau FN; Guerrero-Urbano T; Jay G; Norman A; Horwich A; Dearnaley DP
    Clin Oncol (R Coll Radiol); 2001; 13(4):279-83. PubMed ID: 11554626
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Goto Y
    Int J Urol; 2023 Sep; 30(9):704. PubMed ID: 36482811
    [No Abstract]   [Full Text] [Related]  

  • 46. Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
    Tsang ES; Forbes C; Chi KN; Eigl BJ; Parimi S
    Curr Oncol; 2019 Apr; 26(2):e260-e265. PubMed ID: 31043835
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study.
    Pappot H; von der Maase H; Ullén A; Agerbæk M;
    Invest New Drugs; 2018 Aug; 36(4):615-618. PubMed ID: 29081023
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
    Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
    J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.
    Sonpavde G; Rosenberg JE; Hahn NM; Galsky MD; Bangs R; Sternberg CN; Vogelzang NJ
    J Clin Oncol; 2010 May; 28(13):e205-7; author reply e208. PubMed ID: 20159797
    [No Abstract]   [Full Text] [Related]  

  • 51. The landscape of immunotherapy in metastatic urothelial carcinoma.
    Teo MY; Iyer G
    Curr Opin Urol; 2019 Nov; 29(6):643-648. PubMed ID: 31567441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
    Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
    Pollera CF; Nelli F
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.
    Liu D; Plimack ER; Hoffman-Censits J; Garraway LA; Bellmunt J; Van Allen E; Rosenberg JE
    JAMA Oncol; 2016 Aug; 2(8):1094-6. PubMed ID: 27310333
    [No Abstract]   [Full Text] [Related]  

  • 56. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
    Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Peeker R
    Eur Urol; 2022 Jun; 81(6):619-620. PubMed ID: 35193774
    [No Abstract]   [Full Text] [Related]  

  • 58. Thoughts on a systematic review and meta-analysis of adjuvant chemotherapy in muscle-invasive bladder cancer.
    Sternberg CN; Sylvester R
    Eur Urol; 2014 Jul; 66(1):55-6. PubMed ID: 24484605
    [No Abstract]   [Full Text] [Related]  

  • 59. [Current developments in the medical treatment of advanced urothelial carcinoma of the bladder].
    Schmid SC; Gschwend JE; Retz M;
    Aktuelle Urol; 2014 Jan; 45(1):55-63; quiz 64-5. PubMed ID: 24500963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.